Work

Platelet-rich plasma in tendinopathies: Current evidence and limits of indication

Year: 2026
Type: article
Abstract: Platelet-rich plasma (PRP) has been proposed as a biologic treatment for symptomatic tendinopathy, yet its clinical use has expanded faster than evidence of an additional benefit over adequately controlled care. This critical narrative review examines the comparative effectiveness of PRP, identifies sources of disagreement between trials, and defines defensible limits to its indication across major tendon sites. Relevant randomized studies, systematic reviews, and clinical practice guidelines were examined through PubMed-indexed literature, Cochrane publications, and professional society sources available up to 2026. For chronic midportion Achilles tendinopathy, larger sham-controlled studies and an updated meta-analysis do not demonstrate clinically important improvements. Similarly, placebo-controlled findings for lateral elbow and patellar tendinopathy do not justify routine use. Rotator cuff recommendations discourage PRP as a first-line strategy or routine injection, despite some positive small trials. A potentially favorable signal in gluteal tendinopathy derives largely from comparisons with corticosteroid, not sham treatment, and must be interpreted alongside evidence supporting education and exercise. Preparation variability, co-interventions, limited long-term safety reporting, and weak identification of responders restrict generalizability. PRP remains a selective, preference-sensitive option in narrowly defined circumstances, not a substitute for progressive loading or a validated method of tendon regeneration.
Language: English
Field: Medicine
Open Access status: hybrid
OpenAlex ID: W7226010442
FWCI:
Cites:
Cited by:
Related to: 10